NCT04763083 - First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

Chronic Lymphocytic LeukaemiaSmall Lymphocytic LymphomaMantle Cell LymphomaFollicular LymphomaDiffuse Large B Cell LymphomaNon-small Cell Lung Cancer (NSCLC)Malignant Melanoma

Interventions

DRUG

NVG-111

Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles

Trial Locations (3)

W1T 7HA

RECRUITING

University College London Hospital, London

Unknown

RECRUITING

Royal Marsden Hospital, London

RECRUITING

The Christie NHS Foundation Trust, Manchester